Financials VALBIOTIS

Equities

Market Closed - Euronext Paris Other stock markets 11:35:28 2024-06-07 am EDT			5-day change	1st Jan Change
2 ^EUR	-5.21%		-48.59%	-60.00%

Jun. 04	Valbiotis Terminates Licensing, Supply Deal With Nestlé Unit	MT
Jun. 04	Valbiotis: share price plummets, Nestlé agreement terminated	CF

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	16.09	46.58	66.56	44.66	62.05	33.29	-	-
Enterprise Value (EV) ¹	8.057	39.01	52.33	31.01	62.05	14.99	2.044	-4.556
P/E ratio	-1.9 x	-11.7 x	-7.29 x	-2.98 x	-	-2.03 x	-2.64 x	15.1 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	8.41 x	9.13 x	24.7 x	15.9 x	9.11 x	6.94 x	1.52 x	2.16 x
EV / Revenue	4.21 x	7.65 x	19.4 x	11 x	9.11 x	3.12 x	0.09 x	-0.3 x
EV / EBITDA	-	-16.5 x	-6.95 x	-2.77 x	-	-1.25 x	-0.23 x	-1.75 x
EV / FCF	-1.54 x	16.5 x	-7.01 x	-3.33 x	-	-1.71 x	-0.65 x	0.47 x
FCF Yield	-65%	6.05%	-14.3%	-30%	-	-58.4%	-154%	211%
Price to Book	-	6.53 x	4.66 x	3.34 x	-	1.21 x	0.56 x	0.34 x
Nbr of stocks (in thousands)	7,183	7,686	9,717	12,405	12,409	15,779	-	-
Reference price ²	2.240	6.060	6.850	3.600	5.000	2.110	2.110	2.110
Announcement Date	4/21/20	3/16/21	3/15/22	3/15/23	4/26/24	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	1.913	5.099	2.693	2.814	6.809	4.8	21.85	15.4
EBITDA ¹	-	-2.37	-7.534	-11.17	-	-12	-9	2.6
EBIT ¹	-5.157	-3.407	-8.475	-12.03	-7.18	-12.8	3.55	1.9
Operating Margin	-269.58%	-66.82%	-314.7%	-427.36%	-105.45%	-266.67%	16.25%	12.34%
Earnings before Tax (EBT)	-	-3.829	-	-	-	-	-	-
Net income ¹	-5.504	-3.829	-8.681	-12.31	-7.368	-12.9	1.35	1.7
Net margin	-287.72%	-75.09%	-322.35%	-437.53%	-108.21%	-268.75%	6.18%	11.04%
EPS ²	-1.180	-0.5200	-0.9400	-1.210	-	-1.040	-0.8000	0.1400
Free Cash Flow ¹	-5.236	2.361	-7.462	-9.303	-	-8.75	-3.15	-9.6
FCF margin	-273.71%	46.3%	-277.09%	-330.6%	-	-182.29%	-14.42%	-62.34%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	4/21/20	3/16/21	3/15/22	3/15/23	4/26/24	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	8.03	7.57	14.2	13.7	-	18.3	31.3	37.9
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-5.24	2.36	-7.46	-9.3	-	-8.75	-3.15	-9.6
ROE (net income / shareholders' equity)	-	-49.7%	-81%	-	-	-62.7%	-29%	2.7%
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-	-
Assets ¹	-	-	-	-	-	-	-	-
Book Value Per Share ²	-	0.9300	1.470	1.080	-	1.740	3.750	6.290
Cash Flow per Share ²	-1.050	0.3600	-0.7800	-0.9100	-	-0.3000	0.2000	-1.000
Capex ¹	0.29	0.33	0.31	0.11	-	0.3	0.4	0.4
Capex / Sales	15.16%	6.51%	11.36%	3.94%	-	6.25%	1.83%	2.6%
Announcement Date	4/21/20	3/16/21	3/15/22	3/15/23	4/26/24	-	-	-

¹EUR in Million²EUR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.11 EUR

Average target price

8 EUR

Spread / Average Target

+279.15%

	1st Jan change	Capi.
VALBIOTIS	-60.00%	36.23M
VERTEX PHARMACEUTICALS INCORPORATED	+19.05%	125B
REGENERON PHARMACEUTICALS, INC.	+14.04%	108B
BIONTECH SE	-4.09%	24.57B
ARGENX SE	+3.23%	22.82B
GENMAB A/S	-10.44%	18.19B
WUXI APPTEC CO., LTD.	-41.74%	16.54B
BEIGENE, LTD.	-12.35%	16.5B
NEUROCRINE BIOSCIENCES, INC.	+2.64%	13.39B
SAREPTA THERAPEUTICS, INC.	+27.36%	11.1B